West Pharmaceutical Services Inc (WST) shareholders
Close on Nov 17, 2026Market cap $28.85BP/E 46.5Yield 0.21%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 6,066,852 | 8.40% | 13G (passive) amendment | Mar 31, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (8.50%) | 5,962,738 | 8.50% | 13G (passive) amendment | Sep 30, 2026 |
| Vanguard Capital Management | 5,397,791 | 7.48% | 13G (passive) | Mar 31, 2026 |
| Vanguard Portfolio Management | 4,102,674 | 5.69% | 13G (passive) | Mar 31, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (5.00%) | 3,559,016 | 5.00% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of WST | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,651,784 | 9.55% | $2.39B | −184,930 | 0.04% |
| Vanguard Capital Management LLC | 4,613,134 | 6.62% | $1.66B | −70,152 | 0.04% |
| Vanguard Portfolio Management LLC | 4,015,766 | 5.76% | $1.44B | −78,243 | 0.06% |
| FMR LLC | 3,574,816 | 5.13% | $1.28B | +2,325,068 | 0.06% |
| State Street Corp | 3,348,698 | 4.81% | $1.20B | +54,920 | 0.04% |
| Artisan Partners Limited Partnership | 2,411,792 | 3.46% | $865.83M | −246,101 | 1.37% |
| Bank of New York Mellon Corp | 2,043,823 | 2.93% | $733.73M | −422,035 | 0.12% |
| Generation Investment Management Llp | 2,028,322 | 2.91% | $728.17M | −215,654 | 7.08% |
| Geode Capital Management, LLC | 1,903,279 | 2.73% | $680.55M | −9,176 | 0.04% |
| T. Rowe Price Investment Management, Inc. | 1,805,019 | 2.59% | $648.00M | −535,384 | 0.42% |
| Morgan Stanley | 1,582,546 | 2.27% | $568.14M | +124,264 | 0.03% |
| JPMorgan Chase & Co | 1,164,527 | 1.67% | $413.03M | +121,110 | 0.02% |
| Brown Advisory Inc | 1,075,309 | 1.54% | $386.04M | −265,568 | 0.60% |
| Longview Partners (Guernsey) LTD | 1,033,826 | 1.48% | $371.14M | −281,577 | 6.03% |
| Invesco Ltd. | 1,009,852 | 1.45% | $362.54M | −46,155 | 0.03% |
| UBS Asset Management Americas Inc | 884,865 | 1.27% | $317.67M | −17,899 | 0.06% |
| Norges Bank | 862,915 | 1.24% | $309.79M | New | 0.03% |
| Goldman Sachs Group Inc | 814,772 | 1.17% | $292.50M | +87,155 | 0.03% |
| Kayne Anderson Rudnick Investment Management LLC | 760,622 | 1.09% | $273.06M | −97,676 | 0.85% |
| TD Asset Management Inc | 731,054 | 1.05% | $262.45M | −37,899 | 0.23% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 830 | 71M | 100.0% | 149 / 305 | 257 / 62 | 8M | 8M |
| Q1 2026 | 755 | 71M | 100.0% | 89 / 263 | 283 / 128 | 18M | 8M |
| Q4 2025 | 804 | 71M | 100.0% | 115 / 266 | 293 / 56 | 9M | 7M |
| Q3 2025 | 758 | 69M | 99.3% | 119 / 272 | 247 / 83 | 7M | 9M |
| Q2 2025 | 731 | 71M | 100.0% | 105 / 269 | 263 / 81 | 7M | 6M |
| Q1 2025 | 714 | 70M | 100.0% | 93 / 274 | 259 / 114 | 10M | 9M |
| Q4 2024 | 747 | 70M | 100.0% | 108 / 295 | 259 / 80 | 7M | 7M |
| Q3 2024 | 731 | 70M | 99.9% | 62 / 295 | 271 / 100 | 13M | 5M |
| Q2 2024 | 777 | 69M | 99.5% | 88 / 277 | 295 / 78 | 5M | 6M |
| Q1 2024 | 777 | 71M | 100.0% | 97 / 290 | 265 / 93 | 5M | 5M |
| Q4 2023 | 783 | 71M | 100.0% | 96 / 262 | 305 / 61 | 6M | 4M |
| Q3 2023 | 758 | 69M | 98.4% | 83 / 243 | 304 / 51 | 4M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
689 funds held WST in Q2 2026, 52% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of WST | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,242,860 | 3.22% | $805.19M | 0.04% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 1,830,358 | 2.63% | $657.10M | 0.04% | Jun 30, 2026 |
| Vanguard Mid-Cap Index Fund | 1,530,738 | 2.20% | $549.53M | 0.25% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 971,699 | 1.39% | $348.84M | 0.04% | Jun 30, 2026 |
| Fidelity Contrafund | 941,600 | 1.35% | $338.03M | 0.19% | Jun 30, 2026 |
| Vanguard Growth Index Fund | 940,525 | 1.35% | $337.65M | 0.09% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 920,656 | 1.32% | $297.20M | 0.04% | May 31, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 894,785 | 1.28% | $321.23M | 1.39% | Jun 30, 2026 |
| Six Circles Managed Equity Portfolio U.S. Unconstrained Fund | 735,505 | 1.06% | $264.05M | 0.78% | Jun 30, 2026 |
| ProShares S&P 500 Dividend Aristocrats ETF | 590,532 | 0.85% | $190.63M | 1.72% | May 31, 2026 |
| AMCAP Fund | 569,887 | 0.82% | $183.97M | 0.19% | May 31, 2026 |
| Invesco S&P 500 Equal Weight ETF | 563,135 | 0.81% | $192.01M | 0.20% | Jul 31, 2026 |
| VanEck Morningstar Wide Moat ETF | 549,144 | 0.79% | $197.14M | 1.70% | Jun 30, 2026 |
| Vanguard Mid-Cap Growth Index Fund | 541,243 | 0.78% | $194.31M | 0.56% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 499,163 | 0.72% | $179.20M | 0.44% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michel Lagarde | President and CEO, Director | 7,850 | 0.01% | Sep 10, 2026 |
| Eric Mark Green | President, CEO and Board Chair, Director | 175,418 | 0.25% | Mar 3, 2026 |
| Annette F. Favorite | Sr. VP & Chief HR Officer | 29,308 | 0.04% | Sep 15, 2026 |
| Robert W. McMahon | SVP & Chief Financial Officer | 3,429 | 0.00% | Aug 12, 2026 |
| Shane Alden Campbell | SVP, Proprietary Segment | 274 | 0.00% | May 14, 2026 |
| Chad Winters | VP, Chief Accounting Officer | 2,419 | 0.00% | Apr 29, 2026 |
| Rodolphe Jean Poussot | SVP, Strategy & Corporate Dev | 691 | 0.00% | Mar 3, 2026 |
| Norman D. Finch Jr. | SVP, GC & Corporate Secretary | – | – | Mar 3, 2026 |
| Charles Witherspoon | VP & Treasurer | 1,430 | 0.00% | Feb 23, 2026 |
| Cindy Reiss-Clark | Chief Commercial Officer | 5,131 | 0.01% | Feb 20, 2025 |
| Bernard Birkett | Sr VP, Chief Financial Officer | 7,669 | 0.01% | Feb 20, 2025 |
| Kimberly Banks MacKay | SVP, GC & Corporate Secretary | 1,605 | 0.00% | Feb 20, 2025 |
| Janet Brutschea Haugen | Director | 2,114 | 0.00% | Oct 2, 2026 |
| Goldman Myla Lai | Director | 20,435 | 0.03% | May 6, 2026 |
| Molly Joseph | Director | 4,398 | 0.01% | May 6, 2026 |
| Douglas A. Michels | Director | 46,496 | 0.07% | May 6, 2026 |
| Robert F. Friel | Director | 5,513 | 0.01% | May 6, 2026 |
| William F. Feehery | Director | 32,519 | 0.05% | May 6, 2026 |
| Deborah L. Keller | Director | 11,560 | 0.02% | May 6, 2026 |
| Paolo Pucci | Director | 11,854 | 0.02% | May 6, 2026 |
| Mark A. Buthman | Director | 44,309 | 0.06% | May 6, 2026 |
| Stephen H. Lockhart | Director | 3,523 | 0.01% | May 6, 2026 |
| Thomas W. Hofmann | Director | 44,637 | 0.06% | May 8, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Annette F. Favorite Sr. VP & Chief HR Officer | Sep 15, 2026 | Option exercise | +2,524 | $89.64 | $226.25K | 24,342 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −2,524 | $365.00 | $921.26K | 21,818 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Sep 14, 2026 | Sale(10b5-1 plan) | −2,500 | $355.00 | $887.50K | 21,818 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Sep 14, 2026 | Option exercise | +2,500 | $89.64 | $224.10K | 24,318 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Sep 11, 2026 | Sale(10b5-1 plan) | −2,500 | $345.00 | $862.50K | 21,818 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Sep 11, 2026 | Option exercise | +2,500 | $89.64 | $224.10K | 24,318 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Sep 8, 2026 | Option exercise | +2,818 | $83.47 | $235.22K | 19,663 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Sep 8, 2026 | Sale | −2,817 | $340.81 | $960.06K | 16,845 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Sep 8, 2026 | Option exercise | +2,817 | $83.47 | $235.13K | 19,662 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Sep 8, 2026 | Option exercise | +2,500 | $89.64 | $224.10K | 19,345 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Sep 8, 2026 | Sale | −2,500 | $340.81 | $852.03K | 16,845 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Sep 8, 2026 | Sale | −2,818 | $340.81 | $960.40K | 16,845 |
| Robert W. McMahon SVP & Chief Financial Officer | Aug 11, 2026 | Tax withholding | −345.52 | $351.37 | $121.41K | 3,429 |
| Robert W. McMahon SVP & Chief Financial Officer | Aug 11, 2026 | Option exercise | +6,354.74 | – | – | 9,784 |
| Robert W. McMahon SVP & Chief Financial Officer | Aug 11, 2026 | Tax withholding | −2,763.68 | $351.37 | $971.07K | 7,021 |
| Robert W. McMahon SVP & Chief Financial Officer | Aug 11, 2026 | Option exercise | +794.47 | – | – | 3,775 |
| Shane Alden Campbell SVP, Proprietary Segment | May 12, 2026 | Tax withholding | −84.33 | $312.07 | $26.32K | 274 |
| Shane Alden Campbell SVP, Proprietary Segment | May 12, 2026 | Option exercise | +296 | – | – | 358 |
| Shane Alden Campbell SVP, Proprietary Segment | May 12, 2026 | Option exercise | +473.59 | – | – | 748 |
| Shane Alden Campbell SVP, Proprietary Segment | May 12, 2026 | Tax withholding | −134.93 | $312.07 | $42.11K | 613 |
| Stephen H. Lockhart Director | May 4, 2026 | Award | +791 | – | – | 3,523 |
| Molly Joseph Director | May 4, 2026 | Award | +791 | – | – | 4,398 |
| Deborah L. Keller Director | May 4, 2026 | Award | +791 | – | – | 11,560 |
| Mark A. Buthman Director | May 4, 2026 | Award | +791 | – | – | 44,309 |
| Robert F. Friel Director | May 4, 2026 | Award | +791 | – | – | 5,513 |
| Janet Brutschea Haugen Director | May 4, 2026 | Award | +791 | – | – | 2,373 |
| William F. Feehery Director | May 4, 2026 | Award | +791 | – | – | 32,519 |
| Goldman Myla Lai Director | May 4, 2026 | Award | +791 | – | – | 20,435 |
| Douglas A. Michels Director | May 4, 2026 | Award | +791 | – | – | 46,496 |
| Paolo Pucci Director | May 4, 2026 | Award | +791 | – | – | 11,854 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Apr 27, 2026 | Option exercise | +2,817 | $83.47 | $235.13K | 19,645 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Apr 27, 2026 | Sale | −2,817 | $305.20 | $859.75K | 16,828 |
| Chad Winters VP, Chief Accounting Officer | Apr 27, 2026 | Option exercise | +896 | $173.22 | $155.21K | 2,419 |
| Chad Winters VP, Chief Accounting Officer | Apr 27, 2026 | Sale | −896 | $300.67 | $269.40K | 1,523 |
| Charles Witherspoon VP & Treasurer | Feb 20, 2026 | Option exercise | +60.22 | – | – | 1,430 |
| Charles Witherspoon VP & Treasurer | Feb 20, 2026 | Tax withholding | −22.07 | $241.12 | $5.32K | 1,408 |
| Rodolphe Jean Poussot SVP, Strategy & Corporate Dev | Feb 20, 2026 | Option exercise | +383.38 | – | – | 691 |
| Rodolphe Jean Poussot SVP, Strategy & Corporate Dev | Feb 20, 2026 | Tax withholding | −129.55 | $241.12 | $31.24K | 561 |
| Chad Winters VP, Chief Accounting Officer | Feb 20, 2026 | Tax withholding | −30.18 | $241.12 | $7.28K | 1,523 |
| Chad Winters VP, Chief Accounting Officer | Feb 20, 2026 | Option exercise | +89.33 | – | – | 1,553 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Feb 18, 2026 | Tax withholding | −35.76 | $248.26 | $8.88K | 17,374 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Feb 18, 2026 | Option exercise | +135.49 | – | – | 17,410 |
| Rodolphe Jean Poussot SVP, Strategy & Corporate Dev | Feb 18, 2026 | Option exercise | +82.3 | – | – | 335 |
| Rodolphe Jean Poussot SVP, Strategy & Corporate Dev | Feb 18, 2026 | Tax withholding | −27.81 | $248.26 | $6.90K | 307 |
| Eric Mark Green President, CEO and Board Chair, Director | Feb 18, 2026 | Tax withholding | −573.55 | $248.26 | $142.39K | 175,161 |
| Eric Mark Green President, CEO and Board Chair, Director | Feb 18, 2026 | Option exercise | +1,318.81 | – | – | 175,734 |
| Charles Witherspoon VP & Treasurer | Feb 17, 2026 | Award | +115.91 | – | – | 1,411 |
| Charles Witherspoon VP & Treasurer | Feb 17, 2026 | Tax withholding | −41.52 | $243.19 | $10.10K | 1,370 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Feb 17, 2026 | Tax withholding | −150.44 | $243.19 | $36.59K | 17,275 |
| Annette F. Favorite Sr. VP & Chief HR Officer | Feb 17, 2026 | Award | +441.96 | – | – | 17,425 |
| Eric Mark Green President, CEO and Board Chair, Director | Feb 17, 2026 | Tax withholding | −1,305.38 | $243.19 | $317.46K | 172,895 |
| Eric Mark Green President, CEO and Board Chair, Director | Feb 17, 2026 | Award | +4,418.77 | – | – | 174,200 |
| Chad Winters VP, Chief Accounting Officer | Feb 17, 2026 | Tax withholding | −50.58 | $243.19 | $12.30K | 1,462 |
| Chad Winters VP, Chief Accounting Officer | Feb 17, 2026 | Award | +149.68 | – | – | 1,513 |
| Robert W. McMahon SVP & Chief Financial Officer | Feb 11, 2026 | Option exercise | +4,230.53 | – | – | 4,231 |
| Robert W. McMahon SVP & Chief Financial Officer | Feb 11, 2026 | Tax withholding | −1,250.03 | $246.16 | $307.71K | 2,980 |
| Robert F. Friel Director | May 6, 2025 | Award | +1,071 | – | – | 4,682 |
| Mark A. Buthman Director | May 6, 2025 | Award | +1,071 | – | – | 42,861 |
| Goldman Myla Lai Director | May 6, 2025 | Award | +1,071 | – | – | 19,424 |
| William F. Feehery Director | May 6, 2025 | Award | +1,071 | – | – | 31,363 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of West Pharmaceutical Services's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,588 shares on Aug 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Thomas W. Hofmann Director | May 7, 2026 | 3,384 | $1.09M | May 7, 2026 | Restricted Stock Vesting |
| Eric Mark Green Officer, Director | Aug 6, 2024 | 30,732 | $9.36M | Aug 6, 2024 | Option Granted 02/23/2016 |
| Thomas W. Hofmann Director | May 10, 2024 | 617 | $225.77K | May 10, 2024 | Restricted Stock Vesting |
| Eric Mark Green Officer, Director | May 7, 2024 | 66,000 | $24.30M | May 7, 2024 | Option Granted - 04/24/2015 |
| Eric Mark Green Officer, Director | Feb 27, 2024 | 64,132 | $23.08M | Feb 27, 2024 | Option Granted - 04/24/2015 |
| Eric Mark Green Officer, Director | Aug 8, 2023 | 44,000 | $17.37M | Aug 8, 2023 | Stock Option Exercise |
| Eric Mark Green Officer, Director | May 9, 2023 | 44,000 | $15.98M | May 9, 2023 | Stock Option Exercise |
| Thomas W. Hofmann Director | May 1, 2023 | 1,212 | $443.08K | May 1, 2023 | Restricted Stock |
Congress trades
12 trades in West Pharmaceutical Services reported by 5 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Lisa McClain MI09 · spouse | Sold | Jul 22, 2025 | $1K–15K | Aug 13, 2025 |
| Lisa McClain MI09 · spouse | Bought | Jun 17, 2025 | $1K–15K | Aug 13, 2025 57 days late |
| Rob Bresnahan PA08 | Sold | Apr 8, 2025 | $1K–15K | May 8, 2025 |
| Rob Bresnahan PA08 | Bought | Feb 25, 2025 | $1K–15K | Mar 27, 2025 |
| Jared Moskowitz FL23 · child | Sold | Feb 13, 2025 | $1K–15K | Mar 6, 2025 |
| Jared Moskowitz FL23 | Sold | Nov 8, 2024 | $1K–15K | Dec 9, 2024 |
| Jared Moskowitz FL23 | Bought | Dec 28, 2023 | $1K–15K | Aug 21, 2024 237 days late |
| Jared Moskowitz FL23 · child | Bought | Dec 28, 2023 | $1K–15K | Jan 22, 2024 |
| Jared Moskowitz FL23 | Bought | Jul 14, 2023 | $1K–15K | Aug 21, 2024 404 days late |
| Rohit Khanna CA17 · child | Bought | Feb 14, 2022 | $1K–15K | Mar 8, 2022 |
| Lamar Smith TX21 | Bought | Jan 18, 2018 | $1K–15K | Feb 14, 2018 |
| Lamar Smith TX21 | Bought | Oct 23, 2017 | $1K–15K | Nov 20, 2017 |
See a number that looks wrong?